Shopping Cart 0
Cart Subtotal
AED 0

Solid Biosciences Inc (SLDB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

Solid Biosciences Inc (Solid Biosciences) is a life science company focused on developing therapies for duchenne muscular dystrophy (DMD). Its pipeline product candidates include SGT-001, a microdystrophin gene therapy administered through adeno-associated virus (AAV) stabilizes dystrophin glycoprotein complex and rescue muscle function; SB-001, a monoclonal antibody to reduce fibrosis and inflammation in DMD patients. Solid Biosciences has development programs across four scientific platforms which include corrective therapies, disease-modifying therapies, disease understanding and assistive devices. The company works in collaboration with University of Massachusetts Medical School, The Duchenne Research Fund, University of Washington, Alex's Wish, and others. Solid Biosciences is headquartered in Cambridge, Massachusetts, the US.

Solid Biosciences Inc (SLDB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Solid Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Solid Biosciences Raises USD50 Million in Series C Financing 10

Solid GT Raises USD42.5 Million in Series B Financing Round 12

Partnerships 13

Synpromics Enters into Research Partnership with Solid Biosciences 13

Solid Biosciences Enters into Agreement with University of Washington 14

Solid Biosciences Enters into Agreement with Strykagen 15

Solid Biosciences Enters into Co-Development Agreement with Northwestern University 16

Debiopharm Enters into Agreement with Solid Biosciences 17

Licensing Agreements 18

Solid Biosciences Enters into Licensing Agreement with Biotech Company 18

Solid Biosciences Enters into Licensing Agreement with University of Michigan 19

Solid GT Enters into Licensing Agreement with University of Missouri 20

Equity Offering 21

Solid Biosciences Raises USD143.8 Million in IPO of Shares 21

Solid Biosciences Inc-Key Competitors 23

Solid Biosciences Inc-Key Employees 24

Solid Biosciences Inc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Aug 10, 2018: Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update 26

May 10, 2018: Solid Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update 28

Mar 29, 2018: Solid Biosciences Reports Full Year 2017 Financial Results and Provides Corporate Update 30

Corporate Communications 32

Sep 13, 2018: Solid Biosciences welcomes Sukumar Nagendran, M.D., to its board Of directors 32

Jun 26, 2018: Solid Biosciences Names Dr. Martin Freed As Board Director 33

Jun 07, 2017: Solid Biosciences Strengthens Leadership Team to Advance Programs for Duchenne Muscular Dystrophy 34

Clinical Trials 35

May 11, 2017: New Preclinical Data Support SGT-001 As A Novel Treatment Approach For Duchenne Muscular Dystrophy 35

Appendix 36

Methodology 36

About GlobalData 36

Contact Us 36

Disclaimer 36


List Of Figure

List of Figures

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Solid Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Solid Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Solid Biosciences Raises USD50 Million in Series C Financing 10

Solid GT Raises USD42.5 Million in Series B Financing Round 12

Synpromics Enters into Research Partnership with Solid Biosciences 13

Solid Biosciences Enters into Agreement with University of Washington 14

Solid Biosciences Enters into Agreement with Strykagen 15

Solid Biosciences Enters into Co-Development Agreement with Northwestern University 16

Debiopharm Enters into Agreement with Solid Biosciences 17

Solid Biosciences Enters into Licensing Agreement with Biotech Company 18

Solid Biosciences Enters into Licensing Agreement with University of Michigan 19

Solid GT Enters into Licensing Agreement with University of Missouri 20

Solid Biosciences Raises USD143.8 Million in IPO of Shares 21

Solid Biosciences Inc, Key Competitors 23

Solid Biosciences Inc, Key Employees 24

Solid Biosciences Inc, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Solid Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Solid Biosciences Inc (Solid Biosciences) is a life science company focused on developing therapies for duchenne muscular dystrophy (DMD). Its pipeline product candidates include SGT-001, a microdystrophin gene therapy administered through adeno-associated virus (AAV) stabilizes dystrophin glycoprotein complex and rescue muscle function; SB-001, a monoclonal antibody to reduce fibrosis and inflammation in DMD patients. Solid Biosciences has development programs across four scientific platforms which include corrective therapies, disease-modifying therapies, disease understanding and assistive devices. The company works in collaboration with University of Massachusetts Medical School, The Duchenne Research Fund, University of Washington, Alex's Wish, and others. Solid Biosciences is headquartered in Cambridge, Massachusetts, the US.

Solid Biosciences Inc (SLDB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Solid Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Solid Biosciences Raises USD50 Million in Series C Financing 10

Solid GT Raises USD42.5 Million in Series B Financing Round 12

Partnerships 13

Synpromics Enters into Research Partnership with Solid Biosciences 13

Solid Biosciences Enters into Agreement with University of Washington 14

Solid Biosciences Enters into Agreement with Strykagen 15

Solid Biosciences Enters into Co-Development Agreement with Northwestern University 16

Debiopharm Enters into Agreement with Solid Biosciences 17

Licensing Agreements 18

Solid Biosciences Enters into Licensing Agreement with Biotech Company 18

Solid Biosciences Enters into Licensing Agreement with University of Michigan 19

Solid GT Enters into Licensing Agreement with University of Missouri 20

Equity Offering 21

Solid Biosciences Raises USD143.8 Million in IPO of Shares 21

Solid Biosciences Inc-Key Competitors 23

Solid Biosciences Inc-Key Employees 24

Solid Biosciences Inc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Aug 10, 2018: Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update 26

May 10, 2018: Solid Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update 28

Mar 29, 2018: Solid Biosciences Reports Full Year 2017 Financial Results and Provides Corporate Update 30

Corporate Communications 32

Sep 13, 2018: Solid Biosciences welcomes Sukumar Nagendran, M.D., to its board Of directors 32

Jun 26, 2018: Solid Biosciences Names Dr. Martin Freed As Board Director 33

Jun 07, 2017: Solid Biosciences Strengthens Leadership Team to Advance Programs for Duchenne Muscular Dystrophy 34

Clinical Trials 35

May 11, 2017: New Preclinical Data Support SGT-001 As A Novel Treatment Approach For Duchenne Muscular Dystrophy 35

Appendix 36

Methodology 36

About GlobalData 36

Contact Us 36

Disclaimer 36


List Of Figure

List of Figures

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Solid Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Solid Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Solid Biosciences Raises USD50 Million in Series C Financing 10

Solid GT Raises USD42.5 Million in Series B Financing Round 12

Synpromics Enters into Research Partnership with Solid Biosciences 13

Solid Biosciences Enters into Agreement with University of Washington 14

Solid Biosciences Enters into Agreement with Strykagen 15

Solid Biosciences Enters into Co-Development Agreement with Northwestern University 16

Debiopharm Enters into Agreement with Solid Biosciences 17

Solid Biosciences Enters into Licensing Agreement with Biotech Company 18

Solid Biosciences Enters into Licensing Agreement with University of Michigan 19

Solid GT Enters into Licensing Agreement with University of Missouri 20

Solid Biosciences Raises USD143.8 Million in IPO of Shares 21

Solid Biosciences Inc, Key Competitors 23

Solid Biosciences Inc, Key Employees 24

Solid Biosciences Inc, Subsidiaries 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Solid Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.